These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 16796986)

  • 1. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen.
    Coffee AL; Kuehl TJ; Willis S; Sulak PJ
    Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives.
    Coffee AL; Kuehl TJ; Sulak PJ
    Pharmacotherapy; 2008 May; 28(5):576-83. PubMed ID: 18447656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval.
    Sulak P; Willis S; Kuehl T; Coffee A; Clark J
    Headache; 2007 Jan; 47(1):27-37. PubMed ID: 17355491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen.
    Coffee AL; Sulak PJ; Kuehl TJ
    Contraception; 2007 Jun; 75(6):444-9. PubMed ID: 17519150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pituitary-ovarian hormone levels and symptoms in oral contraceptive users: comparison of a 21/7-day and extended regimen.
    Kuehl TJ; Speikermann AM; Willis SA; Coffee A; Sulak PJ
    J Reprod Med; 2008 Apr; 53(4):266-70. PubMed ID: 18472649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen.
    Sulak PJ; Kuehl TJ; Coffee A; Willis S
    Am J Obstet Gynecol; 2006 Oct; 195(4):935-41. PubMed ID: 16647684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective follow-up of two 21/7 cycles followed by two extended regimen 84/7 cycles with contraceptive pills containing ethinyl estradiol and drospirenone.
    Seidman DS; Yeshaya A; Ber A; Amodai I; Feinstein I; Finkel I; Gordon N; Porat N; Samuel D; Shiran-Makler E; Wolman I
    Isr Med Assoc J; 2010 Jul; 12(7):400-5. PubMed ID: 20862819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
    Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A
    Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol.
    Greco T; Graham CA; Bancroft J; Tanner A; Doll HA
    Contraception; 2007 Jul; 76(1):8-17. PubMed ID: 17586130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms.
    Sangthawan M; Taneepanichskul S
    Contraception; 2005 Jan; 71(1):1-7. PubMed ID: 15639064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of an extended flexible regimen of an oral contraceptive pill containing 20 μg ethinylestradiol and 3 mg drospirenone on menstrual-related symptoms: a randomised controlled trial.
    Machado RB; Pompei LM; Badalotti M; Ferriani R; Cruz AM; Nahas E; Maia H
    Eur J Contracept Reprod Health Care; 2017 Feb; 22(1):11-16. PubMed ID: 27684740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
    Batukan C; Muderris II
    Fertil Steril; 2006 Feb; 85(2):436-40. PubMed ID: 16595223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.
    Brown C; Ling F; Wan J
    J Reprod Med; 2002 Jan; 47(1):14-22. PubMed ID: 11838304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
    Pearlstein TB; Bachmann GA; Zacur HA; Yonkers KA
    Contraception; 2005 Dec; 72(6):414-21. PubMed ID: 16307962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
    Freeman EW
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
    Marr J; Gerlinger C; Kunz M
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Extracontraceptive benefits of EE/DRSP (Yaz) in 24+4 day regimen].
    Bruni Bresciani V
    Minerva Ginecol; 2010 Jun; 62(3):261-6. PubMed ID: 20595950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight.
    Endrikat J; Sandri M; Gerlinger C; Rübig A; Schmidt W; Fortier M
    Eur J Contracept Reprod Health Care; 2007 Sep; 12(3):220-8. PubMed ID: 17763260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of cycle control, side effects and client's satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone (24/4 regimen).
    Chaiyasit N; Taneepanichskul S
    J Med Assoc Thai; 2010 May; 93(5):517-22. PubMed ID: 20524436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.